---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-144952"
form_type: "8-K/A"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:33:13.255458+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022

## Summary
- Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.
- Net assets acquired: $44.1M assets, $5.7M liabilities, net $38.4M as of Dec 31, 2022.
- FY2022 revenue: $43.1M (product $32.3M, service $10.8M); direct expenses $47.5M.
- Abbreviated financials exclude corporate overhead, taxes, interest; not a standalone entity.
- Acquired brands include Amnis, CellStream, Guava, Muse; closing occurred Feb 28, 2023.

## SEC filing metadata
- accession: 0001193125-23-144952
- form_type: 8-K/A
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/0001193125-23-144952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/d467217d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-144952
- JSON: https://secwatch.observer/filing/0001193125-23-144952.json
- Plain text: https://secwatch.observer/filing/0001193125-23-144952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.